Fulcrum data shows clear dose response with pociredir, says Cantor Fitzgerald

Fulctrum Therapeutics has a new corporate deck on their website that features important details since the readout of the 12mg cohort of the Phase 1b pociredir study in late July, Cantor Fitzgerald tells investors. What stands out most, the firm says, is a graph that shows a clear dose response, highlighting a greater than 2-fold HbF induction from the 12mg cohort, despite a more challenging group of patients treated. The firm, which has an Overweight rating and $15 price target on the shares, sees more than 100% upside on the valuation without even reflecting the potential of the 20mg cohort.